Avecho Biotechnology Ltd Total Assets
Avecho Biotechnology Ltd total assets. Based on the latest financial reports, Avecho Biotechnology Ltd (AVE) holds total assets worth AU$8.41 Million AUD (≈ $5.95 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see AVE stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Avecho Biotechnology Ltd (1993–2025)
Total assets of Avecho Biotechnology Ltd from 1993 to 2025. This chart illustrates how Avecho Biotechnology Ltd's total assets have evolved over time, based on quarterly financial data. See latest Avecho Biotechnology Ltd stock price today for real-time trading data and today's change.
Avecho Biotechnology Ltd - Asset Composition Analysis
Avecho Biotechnology Ltd Total Assets Breakdown (December 2025)
Avecho Biotechnology Ltd total assets breakdown as of December 2025. Avecho Biotechnology Ltd's total assets of AU$8.41 Million consist of 99.3% current assets and 0.7% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 65.6% |
| Accounts Receivable | AU$2.20 Million | 31.0% |
| Inventory | AU$8.07K | 0.1% |
| Property, Plant & Equipment | AU$33.70K | 0.5% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (1993–2025)
This chart illustrates how Avecho Biotechnology Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Avecho Biotechnology Ltd working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Avecho Biotechnology Ltd's current assets represent 99.3% of total assets in 2025, a decrease from 100.0% in 1993.
- Cash Position: Cash and equivalents constituted 65.6% of total assets in 2025, up from 1.2% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1993.
- Asset Diversification: The largest asset category is accounts receivable at 31.0% of total assets.
Avecho Biotechnology Ltd Competitors by Total Assets
Key competitors of Avecho Biotechnology Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Avecho Biotechnology Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.38 | 4.62 | 10.37 |
| Quick Ratio | 5.37 | 4.53 | 10.09 |
| Cash Ratio | 0.00 | 3.88 | 8.05 |
| Working Capital | AU$6.64 Million | AU$5.54 Million | AU$5.53 Million |
Avecho Biotechnology Ltd - Advanced Valuation Insights
This section examines the relationship between Avecho Biotechnology Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 42.54 |
| Latest Market Cap to Assets Ratio | 5.00 |
| Asset Growth Rate (YoY) | 42.2% |
| Total Assets | AU$7.11 Million |
| Market Capitalization | $35.54 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Avecho Biotechnology Ltd's assets at a significant premium (5.00x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Avecho Biotechnology Ltd's assets grew by 42.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Avecho Biotechnology Ltd (1993–2025)
The table below shows the annual total assets of Avecho Biotechnology Ltd from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | AU$7.11 Million ≈ $5.03 Million |
+42.21% |
| 2024-12-31 | AU$5.00 Million ≈ $3.54 Million |
-31.73% |
| 2023-12-31 | AU$7.32 Million ≈ $5.18 Million |
+118.78% |
| 2022-12-31 | AU$3.35 Million ≈ $2.37 Million |
-36.23% |
| 2021-12-31 | AU$5.25 Million ≈ $3.71 Million |
+56.38% |
| 2020-12-31 | AU$3.35 Million ≈ $2.37 Million |
-36.89% |
| 2019-12-31 | AU$5.32 Million ≈ $3.76 Million |
+10.69% |
| 2018-12-31 | AU$4.80 Million ≈ $3.40 Million |
-41.72% |
| 2017-12-31 | AU$8.24 Million ≈ $5.83 Million |
-38.30% |
| 2016-12-31 | AU$13.35 Million ≈ $9.45 Million |
-56.56% |
| 2015-12-31 | AU$30.74 Million ≈ $21.75 Million |
-39.60% |
| 2014-12-31 | AU$50.90 Million ≈ $36.02 Million |
+18.49% |
| 2013-12-31 | AU$42.96 Million ≈ $30.40 Million |
-33.00% |
| 2012-12-31 | AU$64.12 Million ≈ $45.37 Million |
-16.27% |
| 2011-12-31 | AU$76.58 Million ≈ $54.18 Million |
+42.42% |
| 2010-12-31 | AU$53.77 Million ≈ $38.04 Million |
-20.18% |
| 2009-12-31 | AU$67.36 Million ≈ $47.66 Million |
-2.64% |
| 2008-12-31 | AU$69.19 Million ≈ $48.96 Million |
-59.66% |
| 2007-12-31 | AU$171.52 Million ≈ $121.36 Million |
-1.14% |
| 2006-12-31 | AU$173.49 Million ≈ $122.76 Million |
+1.42% |
| 2005-12-31 | AU$171.07 Million ≈ $121.04 Million |
+50.02% |
| 2004-12-31 | AU$114.03 Million ≈ $80.69 Million |
+287.76% |
| 2003-12-31 | AU$29.41 Million ≈ $20.81 Million |
+98.19% |
| 2002-12-31 | AU$14.84 Million ≈ $10.50 Million |
-19.34% |
| 2001-12-31 | AU$18.40 Million ≈ $13.02 Million |
-11.81% |
| 2000-12-31 | AU$20.86 Million ≈ $14.76 Million |
+309.32% |
| 1999-12-31 | AU$5.10 Million ≈ $3.61 Million |
+214.49% |
| 1998-12-31 | AU$1.62 Million ≈ $1.15 Million |
-70.66% |
| 1997-12-31 | AU$5.52 Million ≈ $3.91 Million |
-83.27% |
| 1996-12-31 | AU$33.01 Million ≈ $23.36 Million |
-4.27% |
| 1995-12-31 | AU$34.48 Million ≈ $24.40 Million |
+208.07% |
| 1994-12-31 | AU$11.19 Million ≈ $7.92 Million |
-5.74% |
| 1993-12-31 | AU$11.88 Million ≈ $8.40 Million |
-- |
About Avecho Biotechnology Ltd
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic f… Read more